upgrad outperform
command complement
chang recommend
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect
object report investor consid report singl factor make invest decis
earn preview upgrad outperform
compani report earn thursday feb et call passcod
number use chart shown review section includ share trade
head into/out earn histor case dont time dens text feel free
skim
snapshot upgrad share outperform increas pt reflect greater
confid abil pull away pack suspect time dose
endpoint measur pnh studi could allow show dramat benefit soliri
notic ahu studi arent compar vs soliri clever rememb nv beat
eylea partial base time endpoint measur wed disappoint wasnt abl
pull someth similar compani wouldnt confirm time ldh measur us
tend provid rather conserv guidanc uncertainti regard
impact tax reform see adequ cushion outlook enabl margin
expans soliri mg launch jump front earn upgrad
also comfort jump front result level believ
product need compar safety/efficaci soliri yield much
compel conveni profil gain traction
also see good chanc show superior efficaci soliri pnh especi
consid dose differ enabl superior outcom primari endpoint
would confirm suspicion believ time dose vs soliri
enabl time ldh hemolysi measur dramat favor
solirisjust like saw nv eylea explain fact wed
quit disappoint design trial non-overlap dose regimen
regimen fail take advantag differ endpoint measur
absenc dosing/endpoint measur advantag least rest
support data favor fairli low bar success -- iv infus
accompani rapid convers franchis provid defens franchis
competitor slow advanc
indic coupl case mening test
broader dataset shown signal beyond one would expect
mechan
also partner deliv prove best-in-class
deliveri profil time
see gain ground rest antibodi field improv
cours
head earn upgrad share outperform updat
pt increas outer year estim reflect believ
defens long-term posit compani pull away competitor alxn valuat
declin meaning past month despit larg underwhelm updat
competitor includ roche/chugai rarx radio silenc other nvs/regn still
possibl competitor reveal hand that par even superior think
recent updat suggest alxn core franchis may maintain domin longer
mani expect addit recent deal enabl everi two week monthli
 dose reflect compani long-term think franchis even beyond exist
formul could even lengthen distanc competitor
featur number catalyst three phase read-out expect year pnh
ahu given valid mechan action inhibit indic longer half-
life expect posit provid robust continu momentum
stock cours year well although part base case assumpt think
could opportun show trend superior compar soliri
would provid substanti upsid current level
result indic strong profil present result
phase studi test rang dose frequenc see
phase studi test phase studi dose interv result
ldh reduct similar result seen soliri triumph studi mean
ldh level treatment arm decreas u/l u/l reduct
interestingli dose test studi even higher cohort
studi studi investig load dose given week apart
follow week everi week contrast pnh studi
test weight-bas regimen
averag patient studi would receiv mainten dose
higher averag dose could allow greater efficaci seen
studi potenti opportun demonstr favor profil vs soliri
addit notic alxn pnh studi structur week endpoint
given dose everi week patient arm around peak
dose hand patient soliri arm tail end last
dose unclear defin normal ldh number patient
within normal rang week patient reach normal level
treatment period case endpoint test ldh normal week
think differ dose could enabl easili show superior soliri
furthermor believ differ dose regimen mean soliri
never given week mean creat framework
ldh hemolysi level routin measur week dose
week dose soliri stack favor
dose day soliri dose day
includ day day day
calcul dose differ enabl favor time endpoint
measur describ
patient treat soliri see weaken respons toward
end dose found small studi look daili variat ldh level
saw fluctuat could suggest decreas effect toward end
week period graph show assay measur level
complement activ time follow dose soliri patient increas
patient toward two week mark illustr potenti decreas
effect eculizumab-medi complement inhibit time dose
three phase studi pnh ahu set read year pnh
studi structur non-inferior trial other gener expect
succeed demonstr compar soliri howev compani also
note potenti demonstr trend superior compar soliri
multipl endpoint overal think consist non-inferior result across trial could
provid modest upsid current valuat trend superior
think possibl given factor could afford substanti inflect
recent updat competitor fail impress suggest us
compani franchis still notch competitor efficaci administr
late last year rarx provid interim updat studi
daili subcu inhibitor pnh trial consist cohort soliri nave switch
inadequ respond soliri nave patient data look roughli compar
result soliri phase studi howev import note baselin
level ldh also substanti lower reflect less sever patient popul
importantli soliri switch cohort highlight rarx doesnt appear util
set soliri doesnt patient transfus depend follow
treatment soliri breakthrough hemolysi occur transfus
independ patient breakthrough hemolysi occur highlight
efficaci best par soliri may valu given
 dose sure profil abl differenti meaning
iv dose ultim even weekli monthli
like roche/chugai engin har bodi antibodi ph
depend recycl technolog engag fcrn receptor howev
compani present initi data healthi volunt reveal
profil appear inferior termin half-lif day
compar favor soliri day substanti lower day
suggest frequent dose like requir
addit patient complet complement inhibit higher
iv dose wherea similar studi healthi volunt treat
demonstr treat subject experienc reduct
free baselin elimin patient reach
exceed g/ml
well peopl treat anti-drug antibodi wherea none
healthi volunt treat studi
progress competitor includ nv painstakingli slow
suggest lack commit program difficulti recruit patient
nv patient phase trial pnh still list recruit patient despit
initi post
potenti near-term upsid myasthenia gravi number
indic expect soliri launch myasthenia gravi least
strong launch pnh ahu result may modest upsid
current estim initi launch trajectori pnh shown compani
doesnt segment revenu possibl tell detail ahu ramp sinc
approv pnh
compani recent announc patient treatment
enrol onesourc follow vaccin benefit
verif patient treat well indic robust initi demand
program
base convers physician believ soliri may use
total popul adjust severe/refractori popul recognit
half subset anti-musk antibodi would suit anti-
complement therapi howev uptak demograph swift could
provid near-term upsid number
halozym deal reflect intellig approach busi develop last year
announc collabor use enhanz technolog develop
subcutan formul everi week monthli administr
advanc separ in-hous develop formul
weekli dose partnership could allow even less frequent dose
greater differenti compar competitor overal view deal posit
continu invest compani franchis way defend eventu
competitor greater access cash wed expect engag addit busi
develop expect similar level disciplin deal
still cautiou
altho see like upsid share current level aspect cautiou
pipelin still barren earn call announc scrap
pipelin program partnership beyond allow compani start afresh
build suit earlier stage program although didnt see program highli
promis begin lack meaning diversif away compani
franchis beyond strensiq still discomfort howev compani recent restructur
plan allow addit wiggl room busi develop addit
greater access ex-u cash
nmo read-out riski soliri phase data nmo expect phase result
indic encourag robust trial mechanist hazi soliri
work set result could volatil stock around
read-out dont think investor high expect head data
prevent studi patient random receiv either soliri placebo
primari endpoint time first relaps previous present result
small phase open-label trial patient demonstr patient
relapse-fre month treatment soliri compar median
attack per person year prior enrol trial
although result phase studi encourag activ
control arm difficult decis conclud benefit confer soliri
addit mechanist unclear soliri abl cross blood brain barrier
would hinder abil treat diseas produc
complement system inhibit may suffici treat diseas
focal point
phase result pnh ahu
pipelin busi develop updat
here share trade histor around quarter left column nbi adjust
red mean trade green mean trade blue move
follow chart highlight product-specif perform past quarter red miss
green beat blue in-lin
actual quarterli perform along consensu vs estim
here matter key line item head
total expensescog incom firstord analyt compani evr isi estim quarterli evr isi focuscommentsolirismyasthenia gravi ahus/pnh market share competit complementmyasthenia gravi track initi launch trajectori continu growth new patient start ahu pnh increas competit player includ roch nv rarx apelli pressur soliri sale due trial recruitmentstrensiqhpp penetrationsolid growth sinc launch look addit indic increas penetr diagnosi patient intern market growth kanumagrowth lal-dsal sluggish sinc launch note increas rate diagnosi resultsupcom phase read-out pnh ahu pipelineupd partnership updat bd rare diseas program hematolog nephrolog neurolog metabol disordersmacro/otherrestructur fx tax reform othersupd announc restructur plan move boston impact margin potenti busi develop potenti impact tax reform updat latamsourc compani report evr isi analyst commentari area focu upcom earn februari
here product-level perform commentari prior quarter
prevent nmosd data enrol prevent nmosd studi enrol prevent nmosd studi enrol prevent nmosd data nmo complet data file regulatori submiss file regulatori submiss us europesoliri mg applic accept review earli know ad commsoliri mg pdufa oct posit mg chmp opinion japan decis earli approv dgf data protect studi meet primari endpoint protect studybegin enrol pnh registr trial enrol pnh switch studi pnh soliri nave studi enrol pnh switch studi pnh soliri nave studi enrol pnh studi soliri nave data pnh soliri nave data enrol ahu registr trial enrol adult adolesc ahu studi enrol adult adolesc ahu studi enrol pnh switch studi pnh soliri switch studi enrol complet data enrol pediatr ahu studi enrol pediatr ahu studi enrol adult enrol earli adolesc ahu studi ahu adult complet enrol earli ahu pede underwaycommenc result support advanc result support advanc start singl pk bridg studi pt pend devic work stabil test human factor testingapprov iv pnh patient japan decis earli enrol pt pivot studi mocd type enrol pt pivot studi mocd type enrol pt pivot studi mocd type adepriorit partnership blueprint arbusnew biz dev team form focu qualiti rare/ultra-rar sens urgenc aml trial initi studi pt advanc solid initi studi pt advanc solid complet dose reduc invest fulli written evalu higher dose studysourc compani reportsoth pipelinesoliri product outlook commentari februari
track guidanc detail past quarter
here alxn actual compar annual guidanc given start year
end soliri limit mg contribut start later year earli mg launch germanytri expect limit growth total sg total oper margin total expect tax epsupp end expect growth yoy singl midpoint compani reportsannu revenu guidanc convert follow year guidanc earningsactu result actual vs guidanc earn guidanc vs guidanc actual result actual vs guidanc earn guidanc vs guidanc actual result actual vs guidancetot enu rangesoliri sale total ranger sg non-gaap tax outstand compani transcript press releas februari
price histori key product shown last modestli increas price soliri
follow chart show larg biopharma histor valuat rang metric
highlight arrow factset
productproduct detailswac price changeeffect solut iv solut wolter kluwer clinic drug inform inc wkcdi copyright wolter kluwer clinic drug inform inc wkcdi endors data view opinion find express herein document materi prepar behalf evercor isi employe solirissoliri iv solut februari
last n/m last factset tax adjust adjust reflect sni jvev/fcfev/ebitdaroicstock perform vs nbi absolut price-to-earnings estimatesr salesprice/ earn ad year ep compound-annual-growth-rate estim year ep compound-annual-growth-rate estimatesep yr compound-annual-growth-rate deltap/e/gconsensu ptcurrent priceconsensu rate buy sell average analyst pt vs currentlast performancelast performancefcf yielddividend yieldavg ep beat last quarter ep beat last quartersshort interestev mm comparison metric larg cap biotechcompanymkt cap mm februari
last n/a n/a factset tax adjustedev/fcfev/ebitdaroicstock perform vs nbi absolut price-to-earnings estimatesr salesprice/ earn ad year ep compound-annual-growth-rate estim year ep compound-annual-growth-rate estimatesep yr compound-annual-growth-rate deltap/e/gconsensu ptcurrent priceconsensu rate buy sell average analyst pt vs currentlast performancelast performancefcf yielddividend yieldshort interestev mm comparison metric pharmacompanymkt cap mm februari
deriv valuat base dcf use discount rate appli commerci
stage biotech compani termin growth rate reflect optimist outlook durabl compani
franchis includ contribut soliri myasthenia gravi nmo given concern scientif merit
indic includ product revenu reflect potenti busi develop
risk price target includ intensifi competit threat formid biopharma compani along potenti
amplifi price pressur failur build compel develop pipelin stumbl develop
trial would expect litani downgrad substanti re-rat
articl articl
time dissemin februari et
analyst josh schimmer steven breazzano maneka mirchandaney ami liu primarili respons prepar
research report attest follow view opinion render research report reflect person view
subject compani issuer part research analyst compens directli relat specif
recommend view research report
